Once-weekly oral islatravir-lenacapavir is noninferior to daily HIV therapy

1. In this phase 3 randomized controlled trial, switching to once-weekly oral islatravir-lenacapavir maintained HIV-1 suppression as effectively as continuing once-daily bictegravir-emtricitabine-tenofovir alafenamide. 2. Rates of serious and grade 3 or higher adverse events were similar between groups. CD4+ T-cell and lymphocyte counts remained stable, and no resistance to islatravir or…